This two-day conference will serve as a platform to discuss compliance and transparency areas of key concern. Goal is to unravel compliance challenges, define and learn fair market value and develop a consistent, simple and transparent method and strategy for your company.
Latest advancements in India's healthcare technologies
On the right track to better, personalized healthcare
Bengaluru, Karnataka, April 25th – On May 17th – 18th, Bengaluru's ITC Gardenia, Luxury Collection Hotel will see the country's leading C-level executives, IT experts, and solution providers to reveal what awaits India's healthcare and how to achieve greater effectiveness and quality of life with the help of digitisation and innovation.
India's healthcare system is patchy, with with underfunded and overcrowded hospitals and clinics, and inadequate rural coverage. Latest HIT advances however might help to mitigate some professional and infrastructure deficiencies. Telemedicine has been emerging as a big trend in India, with its market value expected to reach $18.7 million by 2017. Its great potential lies in the ability to bridge rural-urban by extending low-cost consultation and diagnostic facilities to the remotest areas via high-speed Internet and telecommunications.
Furthermore, India's rapidly growing 4G network will enable expansion of mHealth. Currently, there are over 20 mhealth initiatives for spreading awareness of family planning and other ailments – the industry is expected to reach $0.6 billion by 2017.
What other technologies will be used, and how will India be able to squeeze the potential of digital age?
Find out at the upcoming 4th Annual IT Healthcare India Summit, which provides a unique and exclusive platform for CIOs, Vps and IT heads from healthcare facilities to meet and discuss further steps in adopting futuristic technologies.
The summit will also host Honorary guests representing the state of Karnataka – Shri. U.T. Khader Hon‘Ble Minister For Health & Family Welfare, and Dr. Sharan Prakash R. Patil Hon‘Ble Minister For Medical Education & Chairman of Hyderabad-Karnataka Region Development Board (Hkrdb ), who will deliver an inaugural speech on the digitization of healthcare.
The key topics that will be discussed at the event include paperless technologies, digitisation of hospitals, generisation of smart patients, the pivotal role of CIO and much more.
Contact us via email at: firstname.lastname@example.org, or visit our website to learn more about the event.
: +91 80 4900 5000
:+91 80 4900 5100
Fleming. connects people who know the answers, bring you the know-how you seek and the opportunities you desire, creating Critical Business Connections. After 13 years in the business, Fleming. has grown to offer a complete portfolio of Conferences, Trainings, Exhibitions, Blended Learning, and Online Conferences in 5 continents and various industries. More than 50,000 satisfied companies supporting, attending, and endorsing Fleming events and using its services every year prove that Fleming. is the right partner to support your business growth and help you achieve your goals.
Interested in this topic?
Project & Portfolio Management for Pharma and Biotech – EAST
For the upcoming Project and Portfolio Management for Pharma and Biotech Conference, Fleming presents a high-level meeting building on more than a decade of experience in running global Pharma PPM events worldwide.
Patient Adherence and Engagement
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
White Paper: Beyond the Cold Chain
Take a Good Look at the Future of Corporate Universities
There are four things corporate universities can do to avoid becoming irrelevant in the digital age.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?